Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IoM Report On Postmarketing Study Ethics Could Drive Broad Overhaul Of Informed Consent

Executive Summary

An Institute of Medicine report on ethical and scientific issues in drug safety studies could lead to a broad restructuring of informed consent documents in postmarketing clinical trials

You may also be interested in...



FDA Pushes Back Against “Living” Benefit-Risk Assessment Management Plan

The Institute of Medicine urges the agency to create a publicly available document setting forth benefits and risks of drugs, with periodic updates, but FDA says it has no extra resources to handle such an effort.

Brilinta Advisory Cmte. Nod Creates Postmarketing Study Quandary For FDA

With the Cardiovascular and Renal Drugs Advisory Committee's endorsement of AstraZeneca's antiplatelet agent Brilinta (ticagrelor) behind it, FDA now faces a potential challenge in devising a postmarketing study commitment aimed at addressing efficacy questions in U.S. acute coronary syndrome patients that does not also run into ethical roadblocks

Brilinta Advisory Cmte. Nod Creates Postmarketing Study Quandary For FDA

With the Cardiovascular and Renal Drugs Advisory Committee's endorsement of AstraZeneca's antiplatelet agent Brilinta (ticagrelor) behind it, FDA now faces a potential challenge in devising a postmarketing study commitment aimed at addressing efficacy questions in U.S. acute coronary syndrome patients that does not also run into ethical roadblocks

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel